Live
Endpoints NewsFDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approvalEndpoints NewsTender offer for Recordati; Sobi's gout drug passes Phase 3 testBioPharma DiveParkinson’s drug from Biogen, Denali comes up shortFierceBiotechBioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitionsEndpoints NewsWhy one health AI unicorn is giving away its service for freeEndpoints NewsNovartis says Avidity's science could apply beyond muscular dystrophiesBioWorldSelection Therapeutics identifies new Kv1.3 blockersBioWorldIgnis Therapeutics synthesizes new muscarinic M4 receptor PAMsBioWorldTREM2 agonists detailed in Pfizer patentBioWorldShanghai Maxinovel Pharmaceuticals patents new PD-1/ PD-L1 interaction inhibitorsBioWorldHoliday noticePharmaVoiceWho’s winning pharma’s innovation race? The rankings are out.
Thermo Fisher Apr 5, 2026

JB Capital LLC Decreases Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat

JB Capital LLC Decreases Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Original
Body unavailable. Use the original source.